The Non-injectable Insulin Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Non-injectable Insulin Market:
https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report
According to The Business Research Company’s Non-injectable Insulin Global Market Report 2024, The non-injectable insulin market size is expected to see rapid growth in the next few years. It will grow to $2.89 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to continued patient compliance emphasis, persistent needle phobia solutions, further quality of life improvements, continuous safety enhancement, and reduced infection and injury risks. Major trends in the forecast period include technological advancements, evolution of technological solutions, digital health integration, nanotechnology applications, and combination therapies.
The rising obesity and diabetes issues are expected to propel the growth of the non-injectable insulin market going forward. Obesity is a condition characterized by excessive accumulation of body fat, usually resulting from an imbalance between energy intake (calories consumed) and energy expenditure, while diabetes mellitus, often referred to simply as diabetes, is a group of metabolic disorders characterized by high blood sugar levels over a prolonged period. Non-injectable insulin is used to treat diabetes and obesity, with the potential to improve management by addressing barriers to insulin therapy, offering potential weight management benefits, and providing more convenient treatment options. For instance, in 2022, according to the World Heart Federation, a Switzerland-based non-governmental organization, global obesity rates are expected to surge, with an estimated 2.3 billion people in 2021, including children and adults, facing overweight and obesity, this is likely to rise to 2.7 billion by 2025. Furthermore, in April 2023, according to a report published by the British Diabetic Association, a UK-based diabetes charity, in the UK, 4.3 million individuals have diabetes, and more than 2.4 million people in the UK are at high risk of acquiring type 2 diabetes. Registration numbers for 2021–22 are up 148,951 from 2020–21. Therefore, rising obesity and diabetes issues are driving the growth of the non-injectable insulin market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp
The non-injectable insulin market covered in this report is segmented –
1) By Type: Synthetic Insulin, Semi Synthetic Insulin
2) By Product: Pills, Sprays, Other Products
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores
Major companies operating in the non-injectable insulin market are focusing on innovative advancements in drug delivery technologies, such as needle-free oral insulin spray, to improve the lives of people who manage their diabetes with multiple insulin injections. A needle-free insulin spray is a painless and needle-free alternative for regulating blood glucose, offering a convenient option as the doses can be sprayed directly into the mouth. For instance, in November 2023, NiedlFree Technologies, an India-based technology platform, introduced Ozulin, an oral insulin spray. This oral insulin spray is intended to provide a more user-friendly solution for individuals with diabetes, particularly those who may find traditional injectable insulin methods challenging. If approved, Ozulin has the potential to be a game-changer for diabetics, offering a more convenient and pain-free alternative to insulin injections.
The non-injectable insulin market report table of contents includes:
1. Executive Summary
2.Non-injectable Insulin Market Characteristics
3.Non-injectable Insulin Market Trends And Strategies
4.Non-injectable Insulin Market analysis
5.Non-injectable Insulin Market Size And Growth
6.Non-injectable Insulin Segmentation
7.Non-injectable Insulin Regional And Country Analysis
.
.
.
27.Non-injectable Insulin Competitive Landscape And Company Profiles
28. Non-injectable InsulinKey Mergers And Acquisitions
29.Non-injectable Insulin Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Pfizer Inc.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Bristol-Myers Squibb Company
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Recent studies proved that Pandemic Survival Review Pandemic Survival Review reversing diabetes is not impossible.
In fact, two popular cancer drugs seem to be effective both in the prevention and the reversal of diabetes.
The studies, performed on mice at the University of California, San Francisco, revealed that type 1 diabetes can be put into remission in 80% of the cases.
Furthermore, in 80% of the mice on which the medication worked, the results were permanent.Since type 1 diabetes is primarily managed with injectable insulin, such breakthroughs are very important.
As they were deemed safe and effective for cancer patients, having them approved for other diseases will be a lot easier.Reversing diabetes medication has only been experimented in type 1 diabetes.
However, if you suffer from type 2 diabetes, you can also hope that this medication will be perfected for your condition.
Recent studies proved that reversing diabetes is Marine D3 Review not impossible.
In fact, two popular cancer drugs seem to be effective both in the prevention and the reversal of diabetes.
The studies, performed on mice at the University of California, San Francisco, revealed that type 1 diabetes can be put into remission in 80% of the cases.
Furthermore, in 80% of the mice on which the medication worked, the results were permanent.Since type 1 diabetes is primarily managed with injectable insulin, such breakthroughs are very important.
The two cancer drugs could be easily approved for use in diabetics.
As they were deemed safe and effective for cancer patients, having them approved for other diseases will be a lot easier.Reversing diabetes medication has only been experimented in type 1 diabetes.
